Clinical trials · Raleigh–Durham, NC
Breast Neoplasms clinical trials in Raleigh–Durham
We’re tracking 14 recruiting breast neoplasms studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Cary, North CarolinaAges 40–75 - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Cary, North CarolinaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Raleigh, North CarolinaAges Any age - NCT06120283RecruitingPhase 1
Study of BGB-43395 alone or with other drugs for advanced solid tumors
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Durham, North CarolinaAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Durham, North CarolinaAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Durham, North CarolinaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Durham, North CarolinaAges 12 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Garner, North CarolinaAges 18 years+ - NCT06995898Recruiting
Blood test study for early cancer detection
This study is testing a new blood test that may help find cancer early. You will give blood samples over a year, and researchers will check them for signs of cancer.
Chapel Hill, North CarolinaAges 45–75 - NCT07225114RecruitingPhase 2
Better ultrasound imaging with contrast before biopsy
This trial tests a new, detailed ultrasound technique that uses a contrast agent (called Definity) to get clearer images of a suspicious area before a biopsy. It may help doctors better see the blood flow in the lesion, which could improve diagnosis.
Chapel Hill, North CarolinaAges 18 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Chapel Hill, North CarolinaAges 18 years+ - NCT07214610Recruiting
Improving breast cancer outcomes in North Carolina
This study looks at why some women with invasive breast cancer do better than others. It combines information from biology, medical history, and lifestyle to find ways to improve care and outcomes.
Chapel Hill, North CarolinaAges 20–74 - NCT07396766Recruiting
BREASTChoice decision aid for breast surgery patients
This study tests a tool called BREASTChoice AIM1-B, which helps people who have had breast surgery make informed choices about their follow-up care. You may be eligible if you had a mastectomy or lumpectomy in the past 8 years for breast cancer or to lower your risk.
Chapel Hill, North CarolinaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chapel Hill, North CarolinaAges Any age
Hear when a new Breast Neoplasms trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Breast Neoplasms trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting breast neoplasms studies listed above.
- University of North Carolina at Chapel Hill · 3 studies
- Duke University Medical Center · 2 studies
- UNC Children's Hospital · 2 studies
- Cone Health Cancer Center at Alamance Regional
- Duke Cancer Center
- Duke Cancer Institute
- Duke University
- Duke University Health System
What taking part in a breast neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting breast neoplasms studies in North Carolina.
Common questions
- Are there breast neoplasms clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 14 recruiting breast neoplasms studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast neoplasms study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast neoplasms studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.